Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, with shareholders holding more than 5% of shares reducing their stake from 5.0051% to 4.7129%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder composition without significant operational impact.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies for cancer, autoimmune, and infectious diseases.
Average Trading Volume: 6,016,162
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.24B
See more data about 1877 stock on TipRanks’ Stock Analysis page.